JP2018524973A5 - - Google Patents

Download PDF

Info

Publication number
JP2018524973A5
JP2018524973A5 JP2017562598A JP2017562598A JP2018524973A5 JP 2018524973 A5 JP2018524973 A5 JP 2018524973A5 JP 2017562598 A JP2017562598 A JP 2017562598A JP 2017562598 A JP2017562598 A JP 2017562598A JP 2018524973 A5 JP2018524973 A5 JP 2018524973A5
Authority
JP
Japan
Prior art keywords
hla
car
isolated
antibody
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017562598A
Other languages
English (en)
Japanese (ja)
Other versions
JP7010473B2 (ja
JP2018524973A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/035916 external-priority patent/WO2016197064A1/en
Publication of JP2018524973A publication Critical patent/JP2018524973A/ja
Publication of JP2018524973A5 publication Critical patent/JP2018524973A5/ja
Priority to JP2021182547A priority Critical patent/JP2022051570A/ja
Application granted granted Critical
Publication of JP7010473B2 publication Critical patent/JP7010473B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017562598A 2015-06-04 2016-06-03 Lym-1およびlym-2標的化car細胞免疫療法 Expired - Fee Related JP7010473B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021182547A JP2022051570A (ja) 2015-06-04 2021-11-09 Lym-1およびlym-2標的化car細胞免疫療法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562171004P 2015-06-04 2015-06-04
US62/171,004 2015-06-04
PCT/US2016/035916 WO2016197064A1 (en) 2015-06-04 2016-06-03 Lym-1 and lym-2 targeted car cell immunotherapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021182547A Division JP2022051570A (ja) 2015-06-04 2021-11-09 Lym-1およびlym-2標的化car細胞免疫療法

Publications (3)

Publication Number Publication Date
JP2018524973A JP2018524973A (ja) 2018-09-06
JP2018524973A5 true JP2018524973A5 (enExample) 2019-06-13
JP7010473B2 JP7010473B2 (ja) 2022-02-10

Family

ID=57441999

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017562598A Expired - Fee Related JP7010473B2 (ja) 2015-06-04 2016-06-03 Lym-1およびlym-2標的化car細胞免疫療法
JP2021182547A Pending JP2022051570A (ja) 2015-06-04 2021-11-09 Lym-1およびlym-2標的化car細胞免疫療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021182547A Pending JP2022051570A (ja) 2015-06-04 2021-11-09 Lym-1およびlym-2標的化car細胞免疫療法

Country Status (9)

Country Link
US (2) US10711064B2 (enExample)
EP (1) EP3302559B1 (enExample)
JP (2) JP7010473B2 (enExample)
CN (1) CN107847601A (enExample)
AU (1) AU2016270474A1 (enExample)
CA (1) CA2987992A1 (enExample)
HK (1) HK1253549A1 (enExample)
IL (1) IL256058B (enExample)
WO (1) WO2016197064A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150104117A (ko) 2012-12-18 2015-09-14 이칸 스쿨 오브 메디슨 엣 마운트 시나이 인플루엔자 바이러스 백신 및 그의 용도
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
KR101605421B1 (ko) 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
JP7591342B2 (ja) * 2016-06-08 2024-11-28 プレシゲン,インコーポレイテッド Cd33特異的キメラ抗原受容体
WO2017218624A1 (en) 2016-06-15 2017-12-21 Icahn School Of Medicine At Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
CN110753754A (zh) * 2017-02-21 2020-02-04 优特力克斯有限公司 Hla-dr car-t组合物以及制备方法和使用方法
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US20200377855A1 (en) * 2017-05-05 2020-12-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rapid method for the culture of tumor infiltrating lymphocytes
CN110892265A (zh) * 2017-06-13 2020-03-17 拜克门寇尔特公司 通过荧光灵敏的流式细胞术检测白细胞来源的微泡
EP3810634A4 (en) 2018-06-21 2022-07-27 Icahn School of Medicine at Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
BR112021002487A2 (pt) 2018-08-10 2021-07-27 Eutilex Co., Ltd. receptor de antígeno quimérico que se liga a hla-dr e célula car-t
TWI850282B (zh) * 2018-11-27 2024-08-01 香港商弘年發展有限公司 用於治療癌症之質體建構體和使用方法
KR20210118945A (ko) * 2019-02-15 2021-10-01 유니버시티 오브 써던 캘리포니아 Lym-1 및 lym-2 항체 조성물 및 개선된 car 구성물
EP3959216A4 (en) 2019-04-24 2023-01-11 Icahn School of Medicine at Mount Sinai ANTI-INFLUENZA B VIRUS NEURAMINIDASE ANTIBODIES AND USES THEREOF
AU2020307673A1 (en) * 2019-06-27 2022-01-20 Eutilex Co., Ltd. Chimeric antigen receptor with 4-1BB costimulatory domain
CA3188656A1 (en) 2020-07-17 2022-01-20 Simurx, Inc. Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
IL313935A (en) * 2021-12-30 2024-08-01 Tr1X Inc CD4+ T cells expressing IL-10 chimeric antigen receptors and uses thereof
CN117106098A (zh) * 2023-07-14 2023-11-24 上海市浦东医院(复旦大学附属浦东医院) Vegfr2和pd-1双靶点三代嵌合抗原受体及其应用
CN117186242A (zh) * 2023-07-14 2023-12-08 上海市浦东医院(复旦大学附属浦东医院) 一种靶向vegfr2和pd-1的双靶点嵌合抗原受体及其应用

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US707993A (en) 1901-05-16 1902-08-26 Clinton J Warren Machine for corking bottles.
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4724212A (en) 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-2 and diagnostic antibody produced thereby
US4724213A (en) 1985-05-24 1988-02-09 Northwestern University Murine hybridoma Lym-1 and diagnostic antibody produced thereby
EP1541682A3 (en) 1988-09-02 2005-07-06 Dyax Corp. Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
SE9101433D0 (sv) 1991-05-13 1991-05-13 Marianne Hansson Recombinant dna sequence and its use
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
ATE463573T1 (de) 1991-12-02 2010-04-15 Medimmune Ltd Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69531148T2 (de) 1994-01-31 2004-04-29 Trustees Of Boston University, Boston Bibliotheken aus polyklonalen antikörpern
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
GB9416721D0 (en) 1994-08-18 1994-10-12 Short Brothers Plc A bias yarn assembly forming device
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
WO1997008320A1 (en) 1995-08-18 1997-03-06 Morphosys Gesellschaft Für Proteinoptimierung Mbh Protein/(poly)peptide libraries
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6924123B2 (en) 1996-10-29 2005-08-02 Oxford Biomedica (Uk) Limited Lentiviral LTR-deleted vector
AU781396B2 (en) 1999-07-20 2005-05-19 Morphosys Ag Novel methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
AU4328801A (en) 2000-02-24 2001-09-03 Xcyte Therapies Inc Simultaneous stimulation and concentration of cells
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7419829B2 (en) 2000-10-06 2008-09-02 Oxford Biomedica (Uk) Limited Vector system
EP1373536B9 (en) 2001-03-13 2009-09-02 Novartis AG Lentiviral packaging constructs
MXPA05006724A (es) 2003-01-07 2005-09-08 Symphogen As Metodo para producir proteinas policlonales recombinantes.
JP2006521810A (ja) 2003-03-11 2006-09-28 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
EP1711527A4 (en) 2003-12-15 2008-09-03 Dendreon Corp HLA-DR SPECIFIC ANTIBODIES, COMPOSITIONS AND METHODS
GB0408449D0 (en) 2004-04-15 2004-05-19 Banerjee Subhasis Diagnostic and therapeutic applications of soluble lhcge protein
US7527947B2 (en) 2004-06-14 2009-05-05 Novozymes A/S Signal peptide for producing a polypeptide
US20060063209A1 (en) 2004-08-20 2006-03-23 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
CN1331887C (zh) * 2004-08-20 2007-08-15 上海美恩生物技术有限公司 抗hla-dr10的淋巴瘤特异性嵌合单抗
CA2599734C (en) * 2005-03-03 2014-01-28 Immunomedics, Inc. Humanized l243 antibodies
WO2007058725A2 (en) 2005-10-12 2007-05-24 The Regents Of The University Of California Engineered antibody fragment that irreversibly binds an antigen
EP4032552B1 (en) 2008-08-26 2023-10-04 City of Hope Method and compositions for enhanced anti-tumor effector functioning of t cells
WO2010060186A1 (en) 2008-11-03 2010-06-03 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN103041387B (zh) 2011-10-11 2014-12-10 苏州工业园区晨健抗体组药物开发有限公司 恶性b细胞淋巴瘤抗体药物的新用途
AU2013222288A1 (en) 2012-02-22 2014-08-14 The Trustees Of The University Of Pennsylvania Use of ICOS-based CARs to enhance antitumor activity and CAR persistence
EA201990959A1 (ru) 2012-04-11 2020-02-10 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные антигенные рецепторы, нацеленные на антиген созревания b-клеток
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
KR101605421B1 (ko) * 2014-03-05 2016-03-23 국립암센터 B 세포 림프종 세포를 특이적으로 인지하는 단일클론항체 및 이의 용도
WO2016160618A2 (en) 2015-03-27 2016-10-06 University Of Southern California Car t-cell therapy directed to lhr for the treatment of solid tumors
US20190031759A1 (en) * 2015-04-30 2019-01-31 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
CN110753754A (zh) 2017-02-21 2020-02-04 优特力克斯有限公司 Hla-dr car-t组合物以及制备方法和使用方法

Similar Documents

Publication Publication Date Title
JP2018524973A5 (enExample)
Chen et al. Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma
JP2018511319A5 (enExample)
Loo et al. Development of an Fc-enhanced anti–B7-H3 monoclonal antibody with potent antitumor activity
Inaguma et al. Construction and molecular characterization of a T-cell receptor-like antibody and CAR-T cells specific for minor histocompatibility antigen HA-1H
Stevenson et al. The meaning and relevance of B-cell receptor structure and function in chronic lymphocytic leukemia
Jain et al. The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine
RU2016131207A (ru) Детерминанты ответа раковой опухоли на иммунотерапию
KR20190101989A (ko) 항 gpc3 항체
JP2022510322A (ja) Cd3抗体およびその医薬用途
WO2018097951A1 (en) Anti-mage-a3/a6 antibodies
JP2013506428A5 (enExample)
Jovčevska et al. TRIM28 and β-actin identified via nanobody-based reverse proteomics approach as possible human glioblastoma biomarkers
EP3526257A2 (en) Modular tetravalent bispecific antibody platform
JP6944925B2 (ja) 組織浸潤nk細胞を検出する方法
WO2013131050A1 (en) Materials and methods for differential treatment of cancer
US9676855B2 (en) B7-H6 therapeutically active monoclonal antibody against B7-H6 polypeptide
WO2021097800A1 (en) Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
JP2021505663A5 (enExample)
Moreno et al. High level of MUC1 in serum of ovarian and breast cancer patients inhibits huHMFG-1 dependent cell-mediated cytotoxicity (ADCC)
Cyr et al. Patient-derived Siglec-6-targeting antibodies engineered for T-cell recruitment have potential therapeutic utility in chronic lymphocytic leukemia
WO2019224385A2 (en) Combined bispecific antibody and immuno-oncology therapies
JP7776446B2 (ja) 抗ヒトlag-3抗体および免疫組織化学(ihc)でのその使用
JP2024517893A (ja) 腫瘍由来細胞外小胞に関する方法
JP2020515286A5 (enExample)